Daré Bioscience Launches First Female Topical Sildenafil Cream Following 200-Woman Trial
Daré Bioscience launched DARE to PLAY™, the first topical sildenafil cream clinically studied for women, showing increased genital blood flow within 10 minutes and improved arousal in a 200-participant randomized placebo-controlled trial. The prescription product is available via Section 503B compounding and telehealth during its Regulation A offering.
1. Launch of DARE to PLAY™
Daré Bioscience introduced DARE to PLAY™, a non-hormonal topical sildenafil cream formulated exclusively for women, designed to deliver sildenafil directly to genital tissue and boost blood flow in about 10 minutes, enhancing sensations of warmth, tingling, swelling and lubrication.
2. Clinical Evidence
The cream underwent a randomized, placebo-controlled trial with 200 women and their partners, demonstrating statistically significant increases in genital blood flow and self-reported arousal based on clinically validated endpoints, marking the first topical sildenafil study focused on female physiology.
3. Commercialization and Financing
DARE to PLAY™ is available as a Section 503B compounded prescription product with telehealth access and pre-fulfillment coverage in all 50 states; Daré is concurrently conducting a Regulation A offering to fund this launch, pursue FDA approval and advance its broader women's health pipeline.